Over the last decade, Infliximab (IFX) an anti-TNF-α drug, has dramatically altered the natural history of IBD, delaying the need for surgery, improving quality of life, and reducing inpatient admissions for IBD [1,2]. The gene discussed is TNF; the disease is inflammatory bowel disease.